In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Attack Of The Hair Restoration Robot

Executive Summary

Robots invaded the operating room years ago, providing surgeons with high precision tools to perform a wide range of procedures from prostatectomies to partial knee replacements. Now, Restoration Robotics is hoping to take over the private practices of hair restoration surgeons. Last year, the venture-backed company launched ARTAS, a robotic system capable of minimally invasive removal of hair follicles used in hair transplants. Restoration Robotics executives see ARTAS as a way to level the playing field between hair restoration surgeons who are capable of performing the sometimes tricky follicular unit extraction and those who want to offer the procedure but don’t have the skills or resources. By conservative estimates, FUE accounts for less than 20% of the $1 billion hair restoration industry. Restoration Robotics sees its robotic system enabling more surgeons to perform FUEs, which could convince more prospective patients to undergo a hair restoration procedure.

You may also be interested in...

Medtech VCs Find Ways To Fill The Gaps

The medtech venture capital ecosystem has certainly felt some strain lately as market pressures tighten the spigot for venture funding. At the IN3 meeting in October, members of a panel of medtech investors – three institutional and one corporate VC, and an entrepreneur – explained how they’re committing their capital during these difficult times.

START-UP’s 2012 Medical Device Census

Our data-driven review of the portfolios of more than two dozen leading medical device VCs show that the median life span of venture-backed companies hovers at seven years. Younger medtech companies are getting by – and getting farther in the regulatory process – with less capital, reflecting the current state of an industry that sees a whole lot of belt tightening in its future.

On the Frontiers of Surgery: An Interview with Fred Moll, MD

Few people have been so integrally connected to surgery's various revolutions as Fred Moll, MD. Two decades ago Moll introduced one of the first enabling tools designed specifically for minimally invasive surgery, ushering in an age of surgery in closed spaces, before turning his attention in the 1990s to surgery's revolution-in-waiting, robotics, helping to launch the MIS revolution, In a recentinterview, Moll talks about those early days, what it was like for a young surgeon to build his first companies, and about the promise of robotics for the future of medicine.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts